EUCTR2005-001430-32-IT进行中（未招募）不适用
A phase III, Randomized, Open - label Study of Lopinavir/Ritonavir tablets versus soft gel capsules and once daily versus twice daily administration, when coadministered with NRTIs in antiretroviral-naive HIV - 1 infected subjects.
Abbott GmBH Co KG0 个研究点目标入组 600 人开始时间: 2006年12月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral Naïve HIV-1 Infected SubjectsHIV-1 infectionEUCTR2005-001430-32-GBAbbott GmbH & Co. KG600
进行中（未招募）
不适用
A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral Naïve HIV-1 Infected SubjectsEUCTR2005-001430-32-DEAbbott GmbH & Co. KG600
进行中（未招募）
不适用
A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral Naïve HIV-1 Infected SubjectsEUCTR2005-001430-32-CZAbbott GmbH & Co. KG600
进行中（未招募）
不适用
A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral Naïve HIV-1 Infected SubjectsHIV-1 infectionEUCTR2005-001430-32-BEAbbott GmbH & Co. KG600
进行中（未招募）
不适用
A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral Naïve HIV-1 Infected SubjectsHIV-1 infectionEUCTR2005-001430-32-GRAbbott GmbH & Co. KG600